KEY POINTS
- The ESTRO Skin and Soft Tissue Focus Group developed comprehensive radiotherapy recommendations for Merkel cell carcinoma (MCC), addressing ten clinical and technical topics across definitive, postoperative, nodal, and palliative treatment. The guideline was informed by a PRISMA-based PubMed search conducted in April 2025 and updated in July 2026, identifying 42 eligible publications from 96 search results, supplemented by existing guidelines and expert consensus. Most supporting evidence remains retrospective, reflecting the rarity of randomized trials in MCC.
- Accurate staging and early treatment initiation are central recommendations. Whole-body FDG PET/CT is preferred for initial staging, with contrast-enhanced CT when PET/CT is unavailable. Sentinel lymph node biopsy is recommended for clinically stage I–II disease when feasible, ideally before reconstructive surgery; occult nodal involvement may be detected in up to 30% of clinically node-negative patients. Pretreatment documentation should include clinical photographs, lesion dimensions, surgical details, histopathological margins, lymphovascular invasion, and relevant nodal findings.
- The guideline recommends 60 Gy in 30 fractions for definitive radiotherapy and at least 50 Gy in 25 fractions postoperatively. Surgery followed by postoperative RT remains an important approach for early-stage disease, although definitive RT is an option for patients who are unsuitable for or decline surgery. Postoperative irradiation may be omitted in carefully selected stage I tumors <2 cm resected with >1-cm negative histological margins, provided other risk factors are favorable. These dose recommendations reflect the available clinical evidence and consensus rather than a single randomized dose-comparison trial.
- Postoperative target volumes should generally include substantial margins around the reconstructed tumor bed. ESTRO recommends a minimum 3-cm radial CTV margin and approximately 1.5-cm depth, or extension to the nearest anatomical barrier such as bone. Margins of up to 5 cm may be considered for gross or higher-risk microscopic disease, including positive margins, lymphovascular invasion, in-transit metastases, or infiltrative histology. Margins must be adapted around critical organs, particularly in head and neck locations, where rigid geometric expansion may be inappropriate.
- Postoperative RT should begin promptly, with delays beyond eight weeks associated with worse outcomes in retrospective data. In a cited cohort of 124 patients, locoregional recurrence was 9.2% when postoperative RT began within eight weeks versus 28.0% when started later. ESTRO emphasizes avoiding unnecessary delays while allowing adequate wound healing. For positive surgical margins, the decision between further excision and prompt postoperative RT should be individualized rather than automatically delaying irradiation for additional surgery.
- Elective nodal irradiation depends on staging findings and recurrence risk. When sentinel node biopsy is positive, further nodal treatment may involve completion lymph node dissection or radiotherapy, with the optimal strategy remaining uncertain. If SLNB cannot be performed, elective nodal irradiation should be considered in higher-risk patients, including those with stage II disease, head and neck primaries, lymphovascular invasion, or immunosuppression. After macroscopic nodal dissection, postoperative nodal RT may be appropriate when locoregional risk is high, particularly with extracapsular extension, although a survival benefit is not established.
- Shorter schedules are relevant to selected palliative and frail patients, but are not universally interchangeable with conventional treatment. Retrospective palliative series reported a 94% objective response rate after 8 Gy in one fraction, including 45% complete responses. Another comparison found more durable control after 24 Gy in three fractions versus 8 Gy in one fraction (95% versus 59%). The guideline also discusses emerging single-fraction postoperative strategies, but their evidence remains insufficient to establish equivalence to conventional adjuvant schedules across all risk groups.
CLINICAL TAKEAWAY
The ESTRO guideline provides a practical framework for radiotherapy in Merkel cell carcinoma, emphasizing accurate staging, prompt postoperative treatment, appropriate target margins, and risk-adapted nodal management. Conventional fractionation remains central for curative treatment, while shorter schedules offer selected alternatives, particularly for patients requiring palliation or unable to tolerate prolonged therapy. Because most recommendations are based on retrospective evidence and expert consensus, treatment should remain individualized through multidisciplinary assessment.